This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Castaman G, Matino D. Hemophilia A and B: molecular and clinical similarities and differences. Haematologica 2019; 104: 1702–1709. doi: 10.3324/haematol.2019.221093.CastamanGMatinoDHemophilia A and B: molecular and clinical similarities and differences20191041702170910.3324/haematol.2019.221093671758231399527Open DOISearch in Google Scholar
Melchiorre D, Linari S, Manetti M, et al. Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A. Haematologica 2016; 101: 219–25. doi: 10.3324/haematol.2015.133462.MelchiorreDLinariSManettiMClinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A20161012192510.3324/haematol.2015.133462493833026494839Open DOISearch in Google Scholar
Kihlberg K, Baghaei F, Bruzelius M, et al. Treatment outcomes in persons with severe haemophilia B in the Nordic region: The B-NORD study. Haemophilia 2021; 27(3): 366–374. doi: 10.1111/hae.14299.KihlbergKBaghaeiFBruzeliusMTreatment outcomes in persons with severe haemophilia B in the Nordic region: The B-NORD study202127336637410.1111/hae.1429933780113Open DOISearch in Google Scholar
Shih MY, Wang JD, Yin JD, et al. Differences in major bleeding events between patients with severe hemophilia A and hemophilia B: a nationwide, population-based cohort study. Clin Appl Thromb Hemost 2019; 25: 1076029619888023. doi: 10.1177/1076029619888023.ShihMYWangJDYinJDDifferences in major bleeding events between patients with severe hemophilia A and hemophilia B: a nationwide, population-based cohort study201925107602961988802310.1177/1076029619888023709820731928075Open DOISearch in Google Scholar
Dolan G, Benson G, Duffy A, et al. Haemophilia B: Where are we now and what does the future hold? Blood Rev 2018; 32(1): 52–60. doi: 10.1016/j.blre.2017.08.007.DolanGBensonGDuffyAHaemophilia B: Where are we now and what does the future hold?2018321526010.1016/j.blre.2017.08.00728826659Open DOISearch in Google Scholar
Clausen N, Petrini P, Claeyssens-Donadel S et al; PedNet and Research of Determinants of Inhibitor development (RODIN) Study Group. Similar bleeding phenotype in young children with haemophilia A or B: a cohort study. Haemophilia 2014; 20: 747–55. doi: 10.1111/hae.12470.ClausenNPetriniPClaeyssens-DonadelSPedNet and Research of Determinants of Inhibitor development (RODIN) Study GroupSimilar bleeding phenotype in young children with haemophilia A or B: a cohort study2014207475510.1111/hae.1247024893572Open DOISearch in Google Scholar
Osooli M, Steen Carlsson K, Astermark J, et al. Surgery and survival in birth cohorts with severe haemophilia and differences in access to replacement therapy: The Malmö experience. Haemophilia 2017; 23(5): e403–e408. doi: 10.1111/hae.13302.OsooliMSteen CarlssonKAstermarkJSurgery and survival in birth cohorts with severe haemophilia and differences in access to replacement therapy: The Malmö experience2017235e403e40810.1111/hae.1330228758324Open DOISearch in Google Scholar
Alprolix Summary of Product Characteristics. Available from https://www.ema.europa.eu/en/documents/product-information/alprolix-epar-product-information_en.pdf (accessed 27 August 2021).Available from https://www.ema.europa.eu/en/documents/product-information/alprolix-epar-product-information_en.pdf (accessed 27 August 2021).Search in Google Scholar
Idelvion Summary of Product Characteristics. Available from https://www.ema.europa.eu/en/documents/product-information/idelvion-epar-product-information_en.pdf (accessed 27 August 2021).Available from https://www.ema.europa.eu/en/documents/product-information/idelvion-epar-product-information_en.pdf (accessed 27 August 2021).Search in Google Scholar
Refixia Summary of Product Characteristics. Available from https://www.ema.europa.eu/en/documents/product-information/refixia-epar-product-information_en.pdf (accesed 27 August 2021).Available from https://www.ema.europa.eu/en/documents/product-information/refixia-epar-product-information_en.pdf (accesed 27 August 2021).Search in Google Scholar
Iorio A, Fischer K, Blanchette V, Rangarajan S, Young G, Morfini M; Pharmacokinetic (PK) Expert Working Group of the International Prophylaxis Study Group (the IPSG). Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates. Thromb Haemost 2017; 117(6): 1023–1030. doi: 10.1160/TH16-12-0942.IorioAFischerKBlanchetteVRangarajanSYoungGMorfiniMPharmacokinetic (PK) Expert Working Group of the International Prophylaxis Study Group (the IPSG)Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates201711761023103010.1160/TH16-12-094228357444Open DOISearch in Google Scholar
Negrier C, Knobe K, Tiede A, et al. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011; 118(10): 2695–701. doi: 10.1182/blood-2011-02-335596.NegrierCKnobeKTiedeAEnhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B201111810269570110.1182/blood-2011-02-33559621555744Open DOISearch in Google Scholar
Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012; 120(12): 2405–11. doi: 10.1182/blood-2012-05-429688.SantagostinoENegrierCKlamrothRSafety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients20121201224051110.1182/blood-2012-05-429688344825522859609Open DOISearch in Google Scholar
Machin N, Ragni MV. An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B. J Blood Med 2018; 9: 135–140. doi: 10.2147/JBM.S159297.MachinNRagniMVAn investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B2018913514010.2147/JBM.S159297Open DOISearch in Google Scholar
Shapiro AD. Concizumab: a novel anti-TFPI therapeutic for hemophilia. Blood Adv 2021; 5(1): 279. doi: 10.1182/bloodadvances.2019001140.ShapiroADConcizumab: a novel anti-TFPI therapeutic for hemophilia20215127910.1182/bloodadvances.2019001140Open DOISearch in Google Scholar
Kahneman D, Tversky A. Judgement under uncertainty: heuristics and biases. Science 1974; 185: 1124–1131. doi: 10.1126/science.185.4157.1124.KahnemanDTverskyAJudgement under uncertainty: heuristics and biases19741851124113110.1126/science.185.4157.1124Open DOISearch in Google Scholar
Tversky A, Kahneman D. Availability: A heuristic for judging frequency and probability. Cognitive Psychology 1973; 5: 207–232. doi: 10.1016/0010-0285(73)90033-9.TverskyAKahnemanDAvailability: A heuristic for judging frequency and probability1973520723210.1016/0010-0285(73)90033-9Open DOISearch in Google Scholar
Srivastava A, Santagostino E, Dougall A, et al.; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26 Suppl 6: 1–158. doi: 10.1111/hae.14046.SrivastavaASantagostinoEDougallAWFH Guidelines for the Management of Hemophilia panelists and co-authorsWFH Guidelines for the Management of Hemophilia, 3rd edition202026Suppl 6115810.1111/hae.1404632744769Open DOISearch in Google Scholar
Mansouritorghabeh H, Mohades ST. Is the detection of factor IX inhibitors in hemophilia B orphan than factor VIII inhibitors in hemophilia A? A concise, systematic review. Cardiovasc Hematol Disord Drug Targets 2020; 20(3): 185–190. doi: 10.2174/1871529X20666200701104143.MansouritorghabehHMohadesSTIs the detection of factor IX inhibitors in hemophilia B orphan than factor VIII inhibitors in hemophilia A? A concise, systematic review202020318519010.2174/1871529X2066620070110414332611303Open DOISearch in Google Scholar
Rendo P, Smith L, Lee HY, et al. Nonacog alfa: an analysis of safety data from six prospective clinical studies in different patient populations with haemophilia B treated with different therapeutic modalities. Blood Coagul Fibrinolysis 2015; 26(8): 912–8. doi: 10.1097/MBC.0000000000000359.RendoPSmithLLeeHYNonacog alfa: an analysis of safety data from six prospective clinical studies in different patient populations with haemophilia B treated with different therapeutic modalities2015268912810.1097/MBC.000000000000035926196195Open DOISearch in Google Scholar
Mahlangu JN. Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B. Ther Adv Hematol 2018; 9(11): 335–346. doi: 10.1177/2040620718802606.MahlanguJNUpdates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B201891133534610.1177/2040620718802606619663130364483Open DOISearch in Google Scholar
Pollard D, Harrison C, Dodgson S, et al. The UK haemophilia specialist nurse: Competencies fit for practice in the 21st century. Haemophilia 2020; 26(4): 622–630. doi: 10.1111/hae.14002.PollardDHarrisonCDodgsonSThe UK haemophilia specialist nurse: Competencies fit for practice in the 21st century202026462263010.1111/hae.14002749622632311205Open DOISearch in Google Scholar
O'Mahony B, Noone D, Prihodova L. Survey of coagulation factor concentrates tender and procurement procedures in 38 European Countries. Haemophilia 2015; 21(4): 436–43. doi: 10.1111/hae.12720.O'MahonyBNooneDPrihodovaLSurvey of coagulation factor concentrates tender and procurement procedures in 38 European Countries20152144364310.1111/hae.1272025996253Open DOISearch in Google Scholar
Hay CR. Purchasing factor concentrates in the 21st century through competitive tendering. Haemophilia 2013; 19(5): 660–7. doi: 10.1111/hae.12169.HayCRPurchasing factor concentrates in the 21st century through competitive tendering2013195660710.1111/hae.1216923711201Open DOISearch in Google Scholar
Garner K, Guelcher C, Pollard D. The use of rIX-FP in patients with haemophilia B: A nurse's perspective. J Haem Pract 2021; 8(1): 86–97. doi: 10.17225/jhp00180.GarnerKGuelcherCPollardDThe use of rIX-FP in patients with haemophilia B: A nurse's perspective202181869710.17225/jhp00180Open DOISearch in Google Scholar
Valentino LA, Blanchette V, Negrier C, et al. Personalising haemophilia management with shared decision making. J Haem Pract 2021; 8(1): 69–79. doi: 10.17225/jhp00178.ValentinoLABlanchetteVNegrierCPersonalising haemophilia management with shared decision making202181697910.17225/jhp00178Open DOISearch in Google Scholar
Buckner TW, Sidonio R Jr, Witkop M, et al. Correlations between patient-reported outcomes and self-reported characteristics in adults with hemophilia B and caregivers of children with hemophilia B: analysis of the B-HERO-S study. Patient Relat Outcome Meas 2019; 10: 299–314. doi: 10.2147/PROM.S219166.BucknerTWSidonioRJrWitkopMCorrelations between patient-reported outcomes and self-reported characteristics in adults with hemophilia B and caregivers of children with hemophilia B: analysis of the B-HERO-S study20191029931410.2147/PROM.S219166675524331572035Open DOISearch in Google Scholar
Cutter S, Guelcher C, Hunter S, et al. Mild-severe hemophilia B impacts relationships of US adults and children with hemophilia B and their families: results from the B-HERO-S study. Patient Relat Outcome Meas 2019; 10: 257–266. doi: 10.2147/PROM.S214188.CutterSGuelcherCHunterSMild-severe hemophilia B impacts relationships of US adults and children with hemophilia B and their families: results from the B-HERO-S study20191025726610.2147/PROM.S214188670162031496854Open DOISearch in Google Scholar
Blamey G, Buranahirun C, Buzzi A, et al. Hemophilia and sexual health: results from the HERO and B-HERO-S studies. Patient Relat Outcome Meas 2019; 10: 243–255. doi: 10.2147/PROM.S211339.BlameyGBuranahirunCBuzziAHemophilia and sexual health: results from the HERO and B-HERO-S studies20191024325510.2147/PROM.S211339669858831616195Open DOISearch in Google Scholar
Buckner TW, Witkop M, Guelcher C, et al. Impact of hemophilia B on quality of life in affected men, women, and caregivers – Assessment of patient-reported outcomes in the B-HERO-S study. Eur J Haematol 2018; 100(6): 592–602. doi: 10.1111/ejh.13055.BucknerTWWitkopMGuelcherCImpact of hemophilia B on quality of life in affected men, women, and caregivers – Assessment of patient-reported outcomes in the B-HERO-S study2018100659260210.1111/ejh.1305529505680Open DOISearch in Google Scholar
Benefix Summary of Product Characteristics. Available from https://www.ema.europa.eu/en/documents/product-information/benefix-epar-product-information_en.pdf (accessed 27 August 2021).Available from https://www.ema.europa.eu/en/documents/product-information/benefix-epar-product-information_en.pdf (accessed 27 August 2021).Search in Google Scholar
Rixubis Summary of Product Characteristics. Available from https://www.ema.europa.eu/en/documents/product-information/rixubis-epar-product-information_en.pdf (accessed 27 August 2021).Available from https://www.ema.europa.eu/en/documents/product-information/rixubis-epar-product-information_en.pdf (accessed 27 August 2021).Search in Google Scholar